{"entity":{"id":"nct05462496","kind":"trial","name":"Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of fOLFIRINOX / mFOLFIRINOX and pembrolizumab in pancreatic cancer, run by Icahn School of Medicine at Mount Sinai, now recruiting.","summary":"Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer is a phase 2, interventional study registered as NCT05462496 by Icahn School of Medicine at Mount Sinai, with a registry enrolment figure of 25 participants, started 2023-03-16 and due to reach its primary completion in 2027-08. Interventions recorded: Biopsy; FOLFIRINOX; Ciprofloxacin; Metronidazole; Pembrolizumab; Surgical Resection. Conditions listed: Pancreatic Cancer. Primary outcome: Achievement of overall immune response; Achievement of overall immune response. Pancreatic eligibility wording from the registry: \"* Histologically confirmed pancreatic adenocarcinoma\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05462496","url":"https://clinicaltrials.gov/study/NCT05462496"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["folfirinox","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05462496","phase":"2","setting":"Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Neoadjuvant Checkpoint-based Immunotherapy Following Chemotherapy in Pancreatic Adenocarcinoma","sponsor":"Icahn School of Medicine at Mount Sinai","enrolled":25,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05462496/","neighbours":{"cancer":[{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}